Portable centrifugal analyzer for the determination of rapid reaction kinetics

Bostick, W.D.; Bauer, Martin; McCracken, R.M.; Mrochek, J.E.

doi:10.1021/ac50052a021

Cited by 5 publications

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For this reason, in the latter portion of the study, 5'N was determined only in those serum samples in which AP had been found to be raised. In a prior preliminary survey of 5'N as a test for liver metastases [45], we found agreement in 75.8070, falsenegative values in 42.9% and false-positive in 10.5%. These results are in general agreement with those reported by Kim et al [13] which were 81.3'70, 35.1'70, and 7.4'70, respectively.…”

Section: Discussionmentioning

confidence: 52%

Biological markers as an aid in the clinical management of patients with liver metastases

Waalkes¹,

Abeloff

Ettinger

et al. 1982

Journal of Surgical Oncology

Self Cite

View full text Add to dashboard Cite

Liver metastases due to the more common neoplastic diseases such as colorectal, breast, or bronchogenic carcinoma are a frequent occurrence and are associated with an ominous prognosis. Earlier detection followed by appropriate therapeutic interventions might have a decided effect on the subsequent course of disease. Controversy exists over the selection of tests with the greatest sensitivity, specificity, and potential utility. Preliminary evidence suggest that gamma-glutamyl transpeptidase and 5'-nucleotidase may be of particular significance. Four enzymes--gamma-glutamyl transpeptidase, 5'-nucleotidase, leucine aminopeptidase, and alkaline phosphatase plus carcinoembryonic antigen--were compared in the same blood samples from selected patients with breast and small cell carcinoma of the lung. Gamma-Glutamyl transpeptidase was the most sensitive test with 28/29 (97%) patients with hepatic metastases having elevated enzymatic activity in their sera. For patients with small cell carcinoma of the lung followed serially, gamma-glutamyl transpeptidase activity was increased an average of 5 months before liver metastases were detected by clinical means. Two factors are important in the interpretation of the results of gamma-glutamyl transpeptidase analysis: (1) Hepatic dysfunction due to diseases other than metastatic tumor involvement can cause a rise in enzyme levels as can (2) medications or ethanol which activate the hepatic microsomal drug metabolizing system. Of particular importance, however, is the fact that antitumor chemotherapy, even intensive and multiple agent, did not appear to effect the enzyme activity in the sera of patients with breast or small cell carcinoma of the lung. Gamma-glutamyl transpeptidase in combination with carcinoembryonic antigen may be of particular value in detecting liver metastases and in assessing subsequent response to therapy.

show abstract

Section: Discussionmentioning

confidence: 52%